Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys Demonstrated favourable safety, consistent with established profile Companies plan to submit data for regulatory approval in the US and EU STOCKHOLM, Aug. 8, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pha ...

CLEVELAND, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter and year ended June 30, 2024, that included the following highlights (compared with the prior year period): Fiscal 2024 Fourth Quarter Highlights: Sales increased 2% to a record $5.2 billion; Organic sales growth was 3% Net income was $785 million, or $884 million adjusted EPS were $6.01, an increase of 10%, or a record $6.77 adjust ...

– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced clearance by the U.S. Foo ...

Q2 operating earnings of $12.2 million; $28.1 million on an adjusted basis, up 95% Q2 revenue down following sale of European staffing operations; up 0.6% on an organic basis Q2 adjusted EBITDA margin increased 170 basis points to 3.7% driven by meaningful reduction in operating expenses resulting from business transformation initiatives and sale of European staffing operations Company expects further expansion of EBITDA margin from the May 31, 2024 acquisition of Motion Recruitment Partners, LLC ("MRP") TR ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 w ...

业务进展 - Wave Life Sciences是一家专注于挖掘RNA药物潜力以改善人类健康的临床阶段生物技术公司 公司宣布了截至2024年6月30日的第二季度财务业绩并提供业务更新[1] - 在HD（等位基因选择性沉默）方面WVE - 003临床数据积极 已提交相关资料给合作伙伴武田并与监管机构接触商讨加速批准路径 预计年底前武田做出决定并得到监管机构反馈[3] - 在DMD（外显子跳跃）方面WVE - N531之前研究达到行业领先的外显子跳跃水平 正在推进FORWARD - 53试验 预计2024年第三季度得到相关数据 若结果积极将推进更广泛的DMD项目[4] - 在AATD（GalNAc - RNA编辑）方面WVE - 006正在进行RestorAATion - 2研究 2024年第三季度已开始给药 预计第四季度得到机制验证数据[5] - 在肥胖症（GalNAc - siRNA）方面WVE - 007有潜力成为一线单一疗法等 计划2025年第一季度开展临床试验 今年将分享更多临床前数据[6][7] - 公司计划2024年秋季举办研发日 将展示创新成果和新的临床前数据 持续推进RNA治疗药物管线[8] 财务亮点 - 截至2024年6月30日现金及现金等价物为1.54亿美元 预计可支持运营至2025年第四季度[9] - 2024年第二季度营收1970万美元 研发费用4040万美元 管理费用1430万美元 净亏损3290万美元[9] 投资者会议 - 公司将于美国东部时间今日上午8:30举行投资者电话会议和网络直播 回顾2024年第二季度财务结果和管线更新[10]

SHENZHEN, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today released a summary of an interview of its Chief Financial Officer, Mr. Shan-Nen Bong with an overseas financial magazine. Interview summary: Interviewer: In the past four quarterly earnings reports, I noticed that your company's gross margin remained between 65% and 72%. This is a fairly high level ...

文章核心观点 - 公司发布了其位于玻利维亚波托西的Silver Sand项目的独立预可行性研究(PFS)技术报告 [1][2] - 该PFS技术报告是根据加拿大证券管理局的国家文书43-101-矿产项目披露标准编制的 [2] - 该PFS技术报告由多名合资格人士编制,包括AMC Mining Consultants、Halyard Inc.和NewFields Canada Mining & Environment ULC等公司的专业人士 [3] - 该技术报告已经过公司勘探副总裁张先生的审核和批准 [4] - 该PFS技术报告可在公司网站、SEDAR+和EDGAR等渠道获取 [5] 公司概况 - 公司是一家加拿大的勘探和开发公司,在玻利维亚拥有三个贵金属项目 [6] - 公司的旗舰项目Silver Sand有潜力成为全球最大的银矿之一 [6] - 公司正在快速推进Carangas项目的初步经济评估,并于2022年完成了Silverstrike项目的发现钻探计划 [6] 前瞻性信息 - 公司对项目的未来开发、勘探、建设等活动做出了前瞻性预测和假设 [9][10][11] - 这些前瞻性信息受到多种风险和不确定因素的影响,可能与实际结果存在差异 [10][11][12] - 公司提醒投资者注意这些风险因素,并表示除法律要求外,公司没有义务更新这些前瞻性信息 [12] 美国投资者警示 - 该新闻稿是根据加拿大证券法编制的,与美国证券法存在差异 [13] - 因此,其中包含的技术和科学信息,包括矿产储量和资源量估算,可能无法与美国公司披露的信息进行比较 [13]

HAIFA, Israel, Aug. 8, 2024 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract worth approximately $130 million to supply Iron Fist Active Protection Systems (APS) to BAE Systems Hägglunds. The systems will be installed on the CV90 Infantry Fighting Vehicle (IFV) as part of a project of a European country. The contract will be performed over a period of five and a half years. The Iron Fist APS is an advanced Hard K ...